BACKGROUND: Stimulatory IgG receptors (FcγRs) on bone marrow-derived cells contribute to the pathogenesis of several autoimmune and inflammatory disorders. Monoclonal antibodies that block FcγRs might suppress these diseases, but they can induce anaphylaxis. OBJECTIVE: We wanted to determine whether a rapid desensitization approach can safely suppress IgG/FcγR-mediated anaphylaxis. METHODS: Mice were injected with serially increasing doses of 2.4G2, a rat mAb that blocks the inhibitory FcγR, FcγRIIb, and the stimulatory receptor, FcγRIII. Rectal temperature was used to detect the development of anaphylaxis. Passive and active IgG-mediated anaphylaxis were evaluated in mice that had been rapidly desensitized with 2.4G2 or mock-desensitized in mice in which monocyte/macrophages, basophils, or neutrophils had been depleted or desensitized and in mice in which FcγRI, FcγRIII, and/or FcγRIV had been deleted or blocked. RESULTS: Rapid desensitization with 2.4G2 prevented 2.4G2-induced shock and completely suppressed IgG-mediated anaphylaxis. Rapid desensitization of ovalbumin-sensitized mice with 2.4G2 was safer and more effective than rapid desensitization with ovalbumin. 2.4G2 treatment completely blocked FcγRIII and removed most FcγRI and FcγRIV from nucleated peripheral blood cells. Because IgG(2a)-mediated anaphylaxis was partially FcγRI and FcγRIV dependent, the effects of 2.4G2 on FcγRI and FcγRIV were probably crucial for its complete inhibition of IgG(2a)-mediated anaphylaxis. IgG(2a)-mediated anaphylaxis was partially inhibited by depletion or desensitization of monocyte/macrophages, basophils, or neutrophils. CONCLUSION: IgG-mediated anaphylaxis can be induced by ligation of FcγRI, FcγRIII, or FcγRIV on monocycte/macrophages, basophils, or neutrophils and can be safely suppressed by rapid desensitization with anti-FcγRII/RIII mAb. A similar approach may safely suppress other FcγR-dependent immunopathology. Published by Mosby, Inc.
BACKGROUND: Stimulatory IgG receptors (FcγRs) on bone marrow-derived cells contribute to the pathogenesis of several autoimmune and inflammatory disorders. Monoclonal antibodies that block FcγRs might suppress these diseases, but they can induce anaphylaxis. OBJECTIVE: We wanted to determine whether a rapid desensitization approach can safely suppress IgG/FcγR-mediated anaphylaxis. METHODS:Mice were injected with serially increasing doses of 2.4G2, a rat mAb that blocks the inhibitory FcγR, FcγRIIb, and the stimulatory receptor, FcγRIII. Rectal temperature was used to detect the development of anaphylaxis. Passive and active IgG-mediated anaphylaxis were evaluated in mice that had been rapidly desensitized with 2.4G2 or mock-desensitized in mice in which monocyte/macrophages, basophils, or neutrophils had been depleted or desensitized and in mice in which FcγRI, FcγRIII, and/or FcγRIV had been deleted or blocked. RESULTS: Rapid desensitization with 2.4G2 prevented 2.4G2-induced shock and completely suppressed IgG-mediated anaphylaxis. Rapid desensitization of ovalbumin-sensitized mice with 2.4G2 was safer and more effective than rapid desensitization with ovalbumin. 2.4G2 treatment completely blocked FcγRIII and removed most FcγRI and FcγRIV from nucleated peripheral blood cells. Because IgG(2a)-mediated anaphylaxis was partially FcγRI and FcγRIV dependent, the effects of 2.4G2 on FcγRI and FcγRIV were probably crucial for its complete inhibition of IgG(2a)-mediated anaphylaxis. IgG(2a)-mediated anaphylaxis was partially inhibited by depletion or desensitization of monocyte/macrophages, basophils, or neutrophils. CONCLUSION: IgG-mediated anaphylaxis can be induced by ligation of FcγRI, FcγRIII, or FcγRIV on monocycte/macrophages, basophils, or neutrophils and can be safely suppressed by rapid desensitization with anti-FcγRII/RIII mAb. A similar approach may safely suppress other FcγR-dependent immunopathology. Published by Mosby, Inc.
Entities:
Keywords:
ATCC; American Type Culture Collection; Anaphylaxis; EW; Egg white; FcγR; HN; HN plus 0.2% NaN3; HNA; Hanks balanced salt solution plus 10% newborn bovine serum; IgG; Monoclonal antibody; OVA; Ovalbumin; PAF; Platelet-activating factor; TNP; Trinitrophenyl; WT; Wild-type; basophil; mAb; macrophage; mouse; neutrophil; rapid desensitization
Authors: Kyung Min Chung; Grant E Nybakken; Bruce S Thompson; Michael J Engle; Anantha Marri; Daved H Fremont; Michael S Diamond Journal: J Virol Date: 2006-02 Impact factor: 5.103
Authors: F D Finkelman; K B Madden; S C Morris; J M Holmes; N Boiani; I M Katona; C R Maliszewski Journal: J Immunol Date: 1993-08-01 Impact factor: 5.422
Authors: Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: Richard T Strait; Suzanne C Morris; Mingyan Yang; Xiao-Wu Qu; Fred D Finkelman Journal: J Allergy Clin Immunol Date: 2002-04 Impact factor: 10.793
Authors: Friederike Jönsson; David A Mancardi; Yoshihiro Kita; Hajime Karasuyama; Bruno Iannascoli; Nico Van Rooijen; Takao Shimizu; Marc Daëron; Pierre Bruhns Journal: J Clin Invest Date: 2011-03-23 Impact factor: 14.808
Authors: Marat V Khodoun; Zeynep Yesim Kucuk; Richard T Strait; Durga Krishnamurthy; Kevin Janek; Ian Lewkowich; Suzanne C Morris; Fred D Finkelman Journal: J Allergy Clin Immunol Date: 2013-04-28 Impact factor: 10.793
Authors: Héloïse Beutier; Caitlin M Gillis; Bruno Iannascoli; Ophélie Godon; Patrick England; Riccardo Sibilano; Laurent L Reber; Stephen J Galli; Mark S Cragg; Nico Van Rooijen; David A Mancardi; Pierre Bruhns; Friederike Jönsson Journal: J Allergy Clin Immunol Date: 2016-04-26 Impact factor: 10.793
Authors: Corey D Clay; Richard T Strait; Ashley Mahler; Marat V Khodoun; Fred D Finkelman Journal: J Allergy Clin Immunol Date: 2017-06-15 Impact factor: 10.793
Authors: R Sharon Chinthrajah; Joseph D Hernandez; Scott D Boyd; Stephen J Galli; Kari C Nadeau Journal: J Allergy Clin Immunol Date: 2016-04 Impact factor: 10.793
Authors: María M Escribese; Domenico Rosace; Tomas Chivato; Tahia D Fernández; Angel L Corbí; Domingo Barber Journal: Front Immunol Date: 2017-05-08 Impact factor: 7.561